Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 4Medulloblastoma 3Brain Neoplasms 3Glioma 2Sarcoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

Nivolumab 8belzutifan 7pembrolizumab 6Ipilimumab 5cabozantinib 3Surveys and Questionnaires 3lenvatinib 2Radiosurgery 2Paclitaxel 2Everolimus 2Carboplatin 2pazopanib 1palbociclib 1liposomal doxorubicin 1guadecitabine 1fludarabine phosphate 1endothelial PAS domain-containing protein 1 1durvalumab 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Technetium Tc 99m Sestamibi 1Taxes 1Sunitinib 1Spermine Synthase 1Social Determinants of Health 1Single Photon Emission Computed Tomography Computed Tomography 1Radiotherapy 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Kidney Neoplasms × Lomustine × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡